Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Nat Microbiol. 2022 Nov 10;7(12):1996–2010. doi: 10.1038/s41564-022-01262-1

Fig. 1. D29 antibody marker level by COVID-19 outcome status.

Fig. 1.

(A) Anti-spike IgG concentration, (B) anti-receptor binding domain (RBD) IgG concentration, and (C) pseudovirus (PsV) neutralization ID50 titer. Data points are from baseline SARS-CoV-2 seronegative per-protocol vaccine recipients in the set [(A-C): N=92 cases, 821 non-cases]. The violin plots contain interior box plots with upper and lower horizontal edges the 25th and 75th percentiles of antibody level and middle line the 50th percentile, and vertical bars the distance from the 25th (or 75th) percentile of antibody level and the minimum (or maximum) antibody level within the 25th (or 75th) percentile of antibody level minus (or plus) 1.5 times the interquartile range. At both sides of the box, a rotated probability density curve estimated by a kernel density estimator with a default Gaussian kernel is plotted. Frequencies of participants with detectable responses were computed with inverse probability of sampling weighting. Pos.Cut, Dectectability/Positivity cut-off. Detectable response for spike IgG was defined by IgG > 10.8424 BAU/ml and for RBD IgG was defined by IgG > 14.0858 BAU/ml. ULoQ, upper limit of quantitation. ULoQ = 238.1165 BAU/ml for spike IgG and 172.5755 BAU/ml for RBD IgG. LLoQ, lower limit of quantitation. Seroresponse for ID50 was defined by a quantifiable value > LLoQ (2.7426 IU50/ml). ULoQ = 619.3052 IU50/ml for ID50. Cases are baseline SARS-CoV-2 seronegative per-protocol vaccine recipients with the primary COVID-19 endpoint (moderate to severe-critical COVID-19 with onset both ≥ 1 day post D29 and ≥ 28 days post-vaccination) up to 54 days post D29 but no later than January 22, 2021.